The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Official Title: A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.
Study ID: NCT01622543
Brief Summary: The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
Detailed Description: Researchers doing this study also want to evaluate the side effects of reolysin when given together with FOLFOX6/ bevacizumab.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Tom Baker Cancer Centre, Calgary, Alberta, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
London Regional Cancer Program, London, Ontario, Canada
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Odette Cancer Centre, Toronto, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
McGill University - Dept. Oncology, Montreal, Quebec, Canada
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Name: Derek Jonker
Affiliation: Ottawa Health Research Institute - General Division
Role: STUDY_CHAIR
Name: Patricia Tang
Affiliation: Tom Baker Cancer Centre, Calgary, Canada
Role: STUDY_CHAIR